Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial

Table 4 Total cumulative dosing and treatment duration

Safety population	AC-1202 n = 86		Placebo n = 66
Total Cumulative Dose
Mean dose (grams) ± SD	3555.00 ± 1883.89		4424.55 ± 1326.78
Median	4515		4965
Median percent of intended dose	86.99%		95.66%
(Range)	(30, 5460)		(150, 5550)
Treatment Duration (days)
N*	82		66
Mean ± SD	71.66 ± 31.08		83.91 ± 18.26
Median	90.0		91.0
(Range)	(1, 101)		(5, 103)
Genotyped population	APOE4(-) n = 36	APOE4(+) n = 39	APOE4(-) n = 27	APOE4(+) n = 33
Total Cumulative Dose
Mean dose (grams)	3049.17	4015.38	4382.22	4375.45
± SD	± 2076.41	± 1531.93	1398.93	± 1386.91
Median	3780	4740	4950	4980
Median percent of intended dose	72.8%	91.3%	95.4%	95.6%
Range (grams)	30 – 5430	30 – 5460	240 – 5490	150 – 5550
Treatment Duration (days)
N*	34	38	27	33
Mean	64.1	77.8	87.1	80.3
± SD	± 36.44	± 24.3	± 11.2	+23.3
Median	88.0	90.0	91.0	91.0
Range (days)	3 – 96	1 – 101	56 – 103	5 – 100

*Treatment duration was unknown for 4 AC-1202 subjects for whom last date of study medication was not recorded

ISSN: 1743-7075